All In Biotech

Drug Trial Radar · NCT01970865

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS

Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

364

Actual

Start

Jan 8, 2014

Primary completion

Mar 15, 2017

Study completion May 24, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .

Conditions

  • ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

Interventions

  • PF-06463922Drug

    Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days

  • CrizotinibDrug

    Oral, starting dose of 250 mg BID continuous daily dosing every 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1Time frame: Cycle 1 (21 days)
  2. Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)Time frame: 3 years

Locations

77 sites in 14 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group/Research

    Fayetteville, Arkansas

  • Highlands Oncology Group

    Rogers, Arkansas

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • UC Irvine Medical Center

    Orange, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavillion (AOP)

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • MDZ: Yale-New Haven Hospital

    New Haven, Connecticut

  • Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Karmanos Center Institute

    Detroit, Michigan

  • Karmanos Cancer Institute

    Farmington Hills, Michigan

  • Siteman Cancer Center-West County

    Creve Coeur, Missouri

  • Barnes-Jewish Hospital

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center-South County

    St Louis, Missouri

  • Rockefeller Patient Pavilion - Memorial Sloan Kettering

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Rochester Regional Health System

    Rochester, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • The Ohio State University

    Columbus, Ohio

  • The Ohio State University

    Columbus, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute (Pharmacy)

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Chris O'Brien Lifehouse

    Sydney, New South Wales, Australia

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia

  • Chris O'Brien Lifehouse

    Sydney Local Health District [rpa], New South Wales, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • University Hospital Antwerp

    Edegem, Belgium

  • British Columbia Cancer Agency-Vancouver Centre

    Vancouver, British Columbia, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.